I’m told by people who are (unfortunately) in a position to know that AstraZeneca has announced cutbacks at their Medimmune division. AZ bought them in 2007, amid worries by some observers that they’d overpaid, and their site in Gaithersburg, MD has become a center of research for the larger company, particularly after a 2013 reorganization.
I don’t have the figures yet, but I’m told that the Oncology division was largely untouched. The rest of the Gaithersburg research structure, though, seems to have been cut back pretty hard, with entire groups being let go along with many longtime employees. As with the Merck layoffs earlier this week, AstraZeneca doesn’t seem to have told anyone else about this, so more details as they become available. Does this concentrate the company’s research even more in their new Cambridge (UK) site?
Update: confirmation from the company.